Connect your AI

Abbott ABT Pharmaceuticals — Remaining performance obligations

Other segment segments

Diagnostic Products

$6.2B+8.8%

Medical Devices

$429M+1.4%

Similar metrics at other companies

ANIPSales of contract manufactured products — Remaining performance obligations

$3.2M—

WHOther — Remaining performance obligation

$18M-45.5%

TNLOther revenue — Remaining performance obligations

$1M0.0%

FCELProduct — Revenue Remaining Performance Obligation

$36.1M-63.2%

OTEXCloud services and subscriptions — Remaining performance obligation

$2.6B+13.0%

CSCOProduct — Remaining performance obligation

$22.06B+6.3%

Other financials

Income statement

Revenue$11.2B+7.8%

Gross profit$6.3B+6.5%

Operating income$1.3B-20.6%

Net income$1.1B-18.7%

EPS (diluted)$0.61-19.7%

Balance sheet

Cash & equivalents$6.8B+4.1%

Total debt$34.0B+157%

Total equity$52.1B+6.7%

Total assets$110.43B+35.6%

Cash flow

Operating cash flow$1.3B-7.2%

CapEx$399.0M-17.6%

Free cash flow$916.0M-1.8%

Valuation

Market cap$162.41B-29.8%

Enterprise value$189.65B-20.3%

P/E25.9×+8.7×

P/S3.6×-1.9×

Profitability

Gross margin56.3%+0.4pp

Operating margin17.1%+0.2pp

Net margin13.9%-18.0pp

FCF margin16.3%+0.6pp

Returns & leverage

Return on equity12.4%-18.4pp

Debt / equity0.7×+0.4×

Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's pharmaceuticals — remaining performance obligations.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Abbott's pharmaceuticals — remaining performance obligations?: Abbott (ABT) reported pharmaceuticals — remaining performance obligations of $258M in Q1 2026.
What does pharmaceuticals — remaining performance obligations mean?: This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period for the pharmaceuticals segment. It reflects the value of contracted revenue that the company expects to recognize in future periods as it fulfills its obligations under existing agreements. This provides visibility into the long-term revenue pipeline and the stability of future cash flows within the branded generics business.